Why is Zomedica stock going up?
Investors are excited about Zomedica's sales primarily because of one reason: They're growing. In the prior-year period, the company didn't generate any revenue at all. Zomedica barely had any sales during the first three quarters of 2021. The difference-maker was the company's acquisition of PulseVet last October.Feb 28, 2022
Is ZOM stock expected to go up?
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +292.16% increase from the last price of 0.31.
Is ZOM still a good stock to buy?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.Jan 7, 2022
Will ZOM stock recover?
ZOM stock will likely struggle to recover in price over the next few months. It's going to be awhile before this early stage company will again have the chance to prove itself to investors.Oct 7, 2021
Will ZOM go up tomorrow?
Tomorrow's movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish. This stock started moving upwards as soon as it opened....Munafa value: 55 as on 08 Fri Apr 2022.Upside target0.33Downside target0.293 more rows
Is Castor Maritime a buy?
The Castor Maritime Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Is ZOM a buy hold or sell?
HC Wainwright is very positive about ZOM and gave it a "Buy" rating on Nov 16, 2020. The price target was changed from $0.50 to $0.30....Predicted Opening Price for Zomedica Pharmaceuticals Corp of Monday, March 28, 2022.Fair opening price March 28, 2022Current price$0.33$0.33 (Undervalued)
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by "changes at our current distributor that we believe have impacted its ability to market our products effectively." Those words likely startled investors, many of whom decided to sell their shares. Zomedica's stock price dropped sharply on Thursday.Apr 15, 2021
Who is Zomedica competition?
Zomedica Pharmaceuticals's top competitors include Patterson Veterinary Supply, Avacta Group, Lintjeshof and KM Biologics. Zomedica Pharmaceuticals is a veterinary pharmaceutical company targeting health and wellness solutions for companion animals (canine, feline and equine).
Is Truforma FDA approved?
In April 2020, Zomedica announced that they had completed platform verification of TRUFORMA, which confirms the achievement of instrument design specifications, and follows FDA Medical Device design control guidelines to ensure the product was built correctly.Jan 12, 2021
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
ZOM POWR Grades
ZOM scores best on the Growth dimension, with a Growth rank ahead of 66.95% of US stocks.
ZOM Stock Summary
ZOM's price/sales ratio is 18,926.23; that's higher than the P/S ratio of 99.78% of US stocks.
ZOM Valuation Summary
ZOM's EV/EBIT ratio is -19.6; this is 166.89% lower than that of the median Healthcare stock.
ZOM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Latest ZOM News From Around the Web
Below are the latest news stories about Zomedica Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.
Signals & Forecast
The Zomedica Pharmaceuticals Corp stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Support, Risk & Stop-loss
Zomedica Pharmaceuticals Corp finds support from accumulated volume at $0.58 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Zomedica Pharmaceuticals Corp stock A Buy?
Zomedica Pharmaceuticals Corp holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
